Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1998 1
2001 1
2005 3
2007 3
2008 2
2009 1
2010 4
2011 4
2012 7
2013 6
2014 13
2015 9
2016 5
2017 9
2018 4
2019 11
2020 10
2021 2
2024 0

Text availability

Article attribute

Article type

Publication date

Similar articles for PMID: 24976972

86 results

Results by year

Filters applied: . Clear all
Page 1
Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial.
Butts C, Socinski MA, Mitchell PL, Thatcher N, Havel L, Krzakowski M, Nawrocki S, Ciuleanu TE, Bosquée L, Trigo JM, Spira A, Tremblay L, Nyman J, Ramlau R, Wickart-Johansson G, Ellis P, Gladkov O, Pereira JR, Eberhardt WE, Helwig C, Schröder A, Shepherd FA; START trial team. Butts C, et al. Lancet Oncol. 2014 Jan;15(1):59-68. doi: 10.1016/S1470-2045(13)70510-2. Epub 2013 Dec 9. Lancet Oncol. 2014. PMID: 24331154 Free article. Clinical Trial.
Tecemotide in unresectable stage III non-small-cell lung cancer in the phase III START study: updated overall survival and biomarker analyses.
Mitchell P, Thatcher N, Socinski MA, Wasilewska-Tesluk E, Horwood K, Szczesna A, Martín C, Ragulin Y, Zukin M, Helwig C, Falk M, Butts C, Shepherd FA. Mitchell P, et al. Ann Oncol. 2015 Jun;26(6):1134-1142. doi: 10.1093/annonc/mdv104. Epub 2015 Feb 26. Ann Oncol. 2015. PMID: 25722382 Free article. Clinical Trial.
Adjuvant MUC vaccination with tecemotide after resection of colorectal liver metastases: a randomized, double-blind, placebo-controlled, multicenter AIO phase II trial (LICC).
Schimanski CC, Kasper S, Hegewisch-Becker S, Schröder J, Overkamp F, Kullmann F, Bechstein WO, Vöhringer M, Öllinger R, Lordick F, Heinemann V, Geißler M, Schulz-Abelius A, Bernhard H, Schön MR, Greil R, Galle P, Lang H, Schmidtmann I, Moehler M. Schimanski CC, et al. Oncoimmunology. 2020 Aug 23;9(1):1806680. doi: 10.1080/2162402X.2020.1806680. Oncoimmunology. 2020. PMID: 32923171 Free PMC article. Clinical Trial.
Tecemotide: an antigen-specific cancer immunotherapy.
Wurz GT, Kao CJ, Wolf M, DeGregorio MW. Wurz GT, et al. Hum Vaccin Immunother. 2014;10(11):3383-93. doi: 10.4161/hv.29836. Hum Vaccin Immunother. 2014. PMID: 25483673 Free PMC article. Review.
LICC: L-BLP25 in patients with colorectal carcinoma after curative resection of hepatic metastases: a randomized, placebo-controlled, multicenter, multinational, double-blinded phase II trial.
Schimanski CC, Möhler M, Schön M, van Cutsem E, Greil R, Bechstein WO, Hegewisch-Becker S, von Wichert G, Vöhringer M, Heike M, Heinemann V, Peeters M, Kanzler S, Kasper S, Overkamp F, Schröder J, Seehofer D, Kullmann F, Linz B, Schmidtmann I, Smith-Machnow V, Gockel I, Lang H, Galle PR. Schimanski CC, et al. BMC Cancer. 2012 Apr 11;12:144. doi: 10.1186/1471-2407-12-144. BMC Cancer. 2012. PMID: 22494623 Free PMC article. Clinical Trial.
86 results